Top Ten most popular articles on Pharmafile.com this week!
July 5, 2019Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Brenntag, Elizabeth Warren, HIV, Novartis, PrEP, cannabis, crispr, pharma
The top story of this week covered Novartis’ announcement that they did not send chemicals that could be used to …
FDA sharpen focus on pharmaceutical companies under Trump
July 5, 2019Medical Communications FDA, Obama, Trump, USA, pharma, regulation
The overall number of warning letters being sent out by the FDA has dropped under President Donald Trump, according to …
NICE recommends Pfizer’s Vizimpro, rejects AstraZeneca’s Tagrisso, in non-small cell lung cancer
July 5, 2019Medical Communications, Sales and Marketing Cancer, NHS, NICE, Pfizer, UK, Vizimpro, lung cancer, pharma
NICE has announced its decision to recommend Pfizer’s Vizimpro (Dacomitinib) in the treatment of non-small-cell lung cancer (NSCLC) – a …
Scientists use cold virus to treat bladder cancer
July 5, 2019Medical Communications, Research and Development CVA21, Cancer, bladder cancer, oncology, oncolytic, pharma, virus
A strain of the virus that causes the common cold has been found to potentially target, infect and kill cancer …
FDA approves multiple myeloma therapy Xpovio despite safety concerns
July 4, 2019Sales and Marketing FDA, Karyopharm, Xpovio, multiple myeloma, pharma
The FDA has made the controversial decision to approve the nuclear export inhibitor Xpovio (selinexor) from Karyopharm Therapeutics, in combination …
Cancer cost US more than $94 billion in lost earnings in 2015
July 4, 2019Research and Development Cancer, economics, health, lost earnings, oncology, pharma
Cancer deaths cost the US economy $94.4 billion in lifetime earnings in 2015, according to figures from the American Cancer …
Prices hiked on 3,400 drugs in first half of 2019
July 4, 2019Research and Development, Sales and Marketing abstruse, access, generics, pharma, prescription, pricing
There have been price hikes on more than 3,400 drugs in the United States in the first six months of …
European approval for Alexion’s Ultomiris in rare blood disease
July 4, 2019Sales and Marketing Alexion, Europe, Ultomiris, paroxysmal nocturnal haemoglobinuria
Alexion has received marketing authorisation from the European Commission for its long-acting C5 complement inhibitor Ultomiris (ravulizumab) in the treatment …
UK Government call for more research into medicinal cannabis
July 4, 2019Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing CBMP, Marijuana, UK, medicinal cannabis, pharma, politics
The British government has called for more research into cannabis-based medicinal products (CBMPs). In a paper published on 3 July, …
ViiV’s Dovato approved in Europe as treatment option for HIV-1
July 3, 2019Research and Development, Sales and Marketing Dovato, GSK, HIV, ViiV Healthcare, pharma
ViiV Healthcare, the specialist HIV firm majority owned by GSK, is celebrating the news that the European Commission has chosen …
Researchers use gene-editing tool CRISPR to cure mice of HIV
July 3, 2019Research and Development AIDS, HIV, Nature Communications, crispr, mice, pharma
American scientists have been able to combine a new form of antiretroviral therapy (ART) with gene editing tool CRISPR/Cas9 to …
Roche’s Xofluza proves non-inferior to Tamiflu in children with flu
July 3, 2019Research and Development Roche, Tamiflu, flu, pharma
Roche has unveiled new Phase 3 data indicating that Xofluza (baloxavir marboxil) was well-tolerated and of comparable efficacy to its …
US Government awarded new patent on preventative HIV drugs PrEP
July 3, 2019Research and Development, Sales and Marketing Gilead, HHS, government, pharma
The Department of Health and Human Services (HHS) has been awarded a new patent on drugs that prevent HIV. The …
Elizabeth Warren calls on former FDA commissioner Scott Gottlieb to resign from board of Pfizer
July 2, 2019Research and Development FDA, Pfizer, Scott Gottlieb, health, pharma, public health
Democrat Presidential candidate Elizabeth Warren has criticised Scott Gottlieb for joining Pfizer. In a letter to Gottlieb, Senator Warren …
Biogen unveils promising new data for Spinraza in pre-symptomatic infants with spinal muscular atrophy
July 2, 2019Manufacturing and Production, Research and Development Biogen, Spinraza, pharma, spinal muscular atrophy
Biogen has introduced new data on the efficacy of Spinraza in the treatment of pre-symptomatic infants in spinal muscular atrophy …
UK industry spend on R&D collaborations grows to £377.3 million
July 2, 2019Manufacturing and Production, Medical Communications, Research and Development ABPI, R&D, pharma
The Association of the British Pharmaceutical Indusxtry (ABPI) has unveiled new data showed that UK industry investment in R&D collaborations …
Roche’s Tecentriq scores CHMP recommendation in PD-L1+ metastatic triple-negative breast cancer
July 2, 2019Manufacturing and Production, Research and Development, Sales and Marketing Roche, breast cancer, pharma, tecentriq
Roche’s immunotherapy Tecentriq (atezolizumab) has been recommended by the EMA’s Committee for Medicinal Products for Human Use (CHMP) in combination …
Libtayo becomes first EU-approved therapy for advanced cutaneous squamous cell carcinoma
July 2, 2019Manufacturing and Production, Sales and Marketing Europe, Libtayo, Regeneron, Sanofi, carcinoma, pharma
The European Commission has revealed that it has decided to award approval, albeit conditionally, to Sanofi and Regeneron’s Libtayo (cemiplimab) …
Hospitals in Oxfordshire to test for susceptibility to dangers of chemotherapy
July 1, 2019Manufacturing and Production Cancer, Diagnostics, NHS, UK, breast, colon, oesophogus, pharma
Hospitals in Oxfordshire have introduced a genetic test which helps doctors predict the dangerous side effects of chemotherapy. In …
Living with mal de debarquement syndrome
July 1, 2019Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing patient experience, pharma, rare disease
Polly Moyer reflects on her experiences living with the rare condition mal de debarquement syndrome, and discusses how connecting with …
Latest content
Five Facts about NHS and primary care
AI in pharma: From lab development to patient impact
